Finasteride for Hair Loss: The Complete Guide (2026)

Last updated: June 2026 | Written by RK

Oral finasteride is the single most-studied prescription drug for androgenetic alopecia, with three decades of randomised trial data behind it, an FDA approval since 1997, and a well-characterised effect size that makes it the backbone of medical hair-loss treatment in most developed countries. It is also the drug that produces more confusion, anxiety and misinformation per gram than perhaps any other in cosmetic dermatology — partly because the side effects are real, partly because the internet amplifies the bad outcomes far more than the good ones, and partly because the underlying biology (DHT and the prostate, sexual function and follicles) is genuinely complex.

This guide is the decision-first version. What the drug actually does, what the trial evidence actually shows, who should and shouldn’t take it, how to start, what to monitor, and what stopping looks like. For the deeper dive into the side-effect data specifically, see finasteride side effects: what the real RCT data shows; for the finasteride-versus-dutasteride decision, see the dedicated comparison.

What finasteride is

Finasteride is a selective inhibitor of 5α-reductase type II, the enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). It was originally developed and approved at higher doses (5 mg/day, brand name Proscar) for benign prostatic hyperplasia in 1992, after which observers noted that men taking it for prostate symptoms grew more scalp hair. The 1 mg/day formulation (Propecia) was approved specifically for male androgenetic alopecia in 1997.

The mechanism is direct enough to explain in a single arc:

For the broader biology — why DHT targets some follicles and spares others, the Type I vs Type II distinction, and the Imperato-McGinley discovery that proved DHT (not testosterone) drives AGA — see DHT and hair loss explained.

The trial evidence

The foundational trial is Kaufman 1998 — a two-year, multicentre, randomised, double-blind, placebo-controlled study of finasteride 1 mg vs placebo in 1,879 men aged 18–41 with vertex or anterior-mid-scalp AGA [1]. The headline results:

• Hair count in the vertex area increased by 11% in the finasteride group at year 2; placebo declined by 3%.
• Standardised global photography rated the finasteride group as improved in 48% of cases and stable in another 42%, vs 7% improved and 25% stable on placebo. Roughly 9 in 10 men on finasteride either held or grew hair over two years; on placebo, roughly 1 in 3 did.
• Patient-rated and investigator-rated assessments consistently favoured finasteride.
• Sexual side-effect rate was 3.8% on finasteride vs 2.1% on placebo — a difference of about 1.7 percentage points that has been the central side-effect number ever since.

Longer-term observational follow-ups out to 5 and 10 years (most notably Yanagisawa 2019 in 523 Japanese men over a decade, 91.5% showing improvement at year 10) have consistently shown that the durable response holds — the gains from the first 1–2 years do not unwind on continued use, and the slope of late progression is meaningfully shallower than the natural-history slope without treatment [3].

For comparison: topical 5% minoxidil’s pivotal Olsen 2002 trial showed a 45% greater hair count change at 48 weeks vs 2% minoxidil; finasteride’s effect against placebo over the same window is larger than this and operates through an entirely different mechanism. The combination of oral finasteride + topical minoxidil is therefore the standard medical stack — covering both the DHT side and the follicle-survival side.

What to expect, month by month

The realistic timeline:

The mirror is a poor instrument for tracking finasteride response. Standardised photos — same room, same lighting, same hair condition (ideally wet and combed back), same four angles, monthly — are the only reliable way to see what is or isn’t happening.

The realistic trajectory: most of the year-1 visible change is “the loss stopped getting worse.” The regrowth, when it comes, lags the stabilisation.

Dosing — standard, lower, and topical

The standard dose is finasteride 1 mg taken once daily. Three legitimate variations exist:

• Standard 1 mg/day — the Kaufman trial dose, and the dose almost every other published RCT used. This is the default unless there is a reason to deviate.
• Lower doses (0.25 mg/day, or 1 mg every other day) — some dermatologists prescribe these for patients with side-effect concerns. The DHT-suppression curve is non-linear, so meaningful suppression continues at sub-1 mg doses, though with less margin. Trial evidence at these lower doses is much smaller than at 1 mg, so the practice is off-label and case-by-case. A reasonable conversation, not a default.
• Topical finasteride — applied to the scalp in a formulated solution, typically 0.25%. Suchonwanit 2022’s review summarised the trial evidence for topical finasteride in AGA, supporting meaningful efficacy with substantially lower serum exposure than oral finasteride [4]. This is the route worth considering specifically for users whose side-effect concerns make oral untenable. See topical finasteride for hair loss for the deep dive.

The 5 mg Proscar tablet is a separate formulation approved for BPH, not hair loss. Some users split it into quarters to approximate a 1.25 mg dose for cost reasons. This works pharmacologically but is off-label and produces uneven splits — generic Propecia 1 mg is now cheap enough that the split-Proscar workaround is largely historical.

Side effects, briefly

The side-effect picture deserves the full article it has — see finasteride side effects: what the real RCT data shows — but the summary for this guide:

• Sexual side effects (decreased libido, erectile difficulty, decreased ejaculate volume) — Kaufman 1998 reported 3.8% on finasteride vs 2.1% on placebo. Most resolve on continued treatment or after stopping.
• Mood changes — depression and anxiety have been reported; whether the population incidence is meaningfully above placebo is contested.
• Gynecomastia — rare; reversible on discontinuation in most cases.
• Post-finasteride syndrome (PFS) — persistent sexual, neurological, or mood symptoms after stopping; rare, contested in the literature, but real for the people who experience them. The mechanism is not well understood. The reported incidence varies widely depending on which study and which definition.

For most users finasteride is well tolerated. For a small minority it is not. The honest framing: small absolute risks, real for the people they happen to, deserving of an informed-consent conversation before starting.

Who shouldn’t take finasteride

A short clinical-judgement list:

• Women who are or could become pregnant. Finasteride is teratogenic — it can cause feminisation of a male fetus. Premenopausal women on finasteride for hair loss (rare; off-label) require reliable contraception. Pregnant women should not even handle crushed or broken tablets.
• Men actively trying to conceive. Finasteride decreases ejaculate volume modestly and has been reported to reduce sperm parameters in some users. Most men’s fertility is not meaningfully affected, but couples having difficulty conceiving should pause the drug and reassess.
• Postmenopausal women. Price 2000’s RCT in 137 postmenopausal women found oral finasteride 1 mg ineffective for hair loss in this specific population [5]. The drug is not contraindicated, but the evidence does not support its use for FPHL in this group — different from the male-pattern situation.
• People with significant baseline mood, sexual, or fertility concerns. The drug can worsen these in a small subset; if those concerns are already in active treatment, deferring finasteride and revisiting after stabilisation is reasonable.
• People with active prostate-cancer screening in progress. Finasteride halves PSA values; any PSA result during treatment must be doubled for interpretation. Coordinate with the urologist or primary-care physician.

How to start

The practical sequence most dermatologists recommend:

1. Get a diagnosis confirmed. Not all hair loss is androgenetic alopecia. Patchy loss (alopecia areata), sudden diffuse shedding (telogen effluvium), scarring scalp inflammation, and frontal fibrosing alopecia in postmenopausal women all need different treatment. A board-certified dermatologist with a trichoscope can resolve this in one visit. The Norwood scale gives the staging for male AGA.
2. Decide on the route. Oral 1 mg/day is the default. Topical finasteride or sub-1mg oral are reasonable alternatives if side-effect concerns are upfront. Telehealth services — see the comparison guide — make the prescription side fast; in-person derm gives the diagnostic depth.
3. Set a calendar. Take photos at baseline (today, before the first pill), then monthly. The drug needs 6–12 months for a verdict, and your memory of “how my hair looked in March” is not reliable.
4. Add minoxidil if not contraindicated. The combination is the standard medical stack — covering DHT and follicle-survival via two different mechanisms. See minoxidil complete guide for that side.
5. Reassess at 12 months. If you are clearly holding or improving, continue. If you are not — and adherence has been consistent — the case for adding topical finasteride, microneedling, or escalating to dutasteride is on the table.

When to stop

Two honest scenarios:

• You want to start a family or your partner is pregnant. Pause the drug 3–6 months before active conception attempts; sperm parameters and ejaculate volume return to baseline. Resume after delivery if desired.
• You develop persistent side effects that don’t resolve. Stop the drug, document the timeline, and consult the prescriber. Most side effects resolve on discontinuation; for the small subset that don’t, post-finasteride syndrome is the framework for the conversation — a separate article will cover that in depth.

Stopping for the sake of stopping — because of social-media pressure or a vague concern — usually unwinds the gains. The hair held by the drug is held by ongoing use; off the drug, susceptible follicles return to baseline DHT exposure and resume miniaturising over 6–12 months. The decision to stop should be an informed one with a doctor, not an internet-driven impulse.

Where finasteride fits

Cost and access in 2026

• Generic finasteride 1 mg — about $15–25/month from a US chain pharmacy with a paper prescription, often less via discount programs. Telehealth services typically run $20–40/month (see the telehealth comparison).
• Brand-name Propecia — several times the generic price with no clinical advantage. Avoid unless there is a specific reason (rare).
• Topical finasteride — compounded; pricier than oral generic, typically $50–100/month depending on concentration and route.
• Insurance — most US insurance plans do not cover finasteride for AGA (an “elective” indication). Annual out-of-pocket is therefore the realistic budget — call it $200–500 for the generic.

For a drug with three decades of RCT data and demonstrable effect, this is one of the least expensive long-term medical commitments in cosmetic dermatology.

What to read next

• Finasteride Side Effects: What the Real RCT Data Shows (2026) — the deep dive on the side-effect data the summary above only touches.
• Finasteride vs Dutasteride for Hair Loss (2026) — when escalation makes sense and when it doesn’t.
• Topical Finasteride for Hair Loss (2026) — the route worth considering when oral side effects are the limiting factor.
• DHT and Hair Loss Explained (2026) — the underlying biology this drug operates on.
• Minoxidil Complete Guide (2026) — the other half of the standard stack.
• Microneedling + Finasteride Stack (2026) — the most-aggressive non-procedural protocol.

References

[1] Kaufman KD, Olsen EA, Whiting D, et al. “Finasteride in the treatment of men with androgenetic alopecia.” J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.

[2] Drake L, Hordinsky M, Fiedler V, et al. “The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.” J Am Acad Dermatol. 1999;41(4):550-554.

[3] Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. “Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia.” Clin Res Trials. 2019;5. DOI: 10.15761/CRT.1000273.

[4] Suchonwanit P, Iamsumang W, Leerunyakul K. “Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature.” J Dermatolog Treat. 2022;33(2):643-648.

[5] Price VH, Roberts JL, Hordinsky M, et al. “Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.” J Am Acad Dermatol. 2000;43(5 Pt 1):768-776.

[6] Olsen EA, Dunlap FE, Funicella T, et al. “A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.” J Am Acad Dermatol. 2002;47(3):377-385.

Disclaimer: This article is educational, not prescriptive. Finasteride is a prescription drug that must be initiated and monitored by a licensed clinician — telehealth or in-person, but a clinician — with informed consent specifically addressing the sexual, mood, and post-finasteride-syndrome considerations relevant to the individual. Treatment decisions for hair loss should account for stage, family history, fertility plans, and personal risk tolerance — not a single article.